• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, November 16, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Computational Screening Identifies Candidate Compound ZINC2770543 as Putative Dual EGFR-Src Binder

by
November 11, 2026
in Health
Reading Time: 3 mins read
0
Computational Screening Identifies Candidate Compound ZINC2770543 as Putative Dual EGFR-Src Binder

Computational Screening Identifies Candidate Compound ZINC2770543 as Putative Dual EGFR-Src Binder

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A computational investigation has identified the purchasable chemical compound ZINC2770543 as a potential dual-binding lead candidate targeting both epidermal growth factor receptor and Src kinase. Using an integrated virtual screening protocol that combined ligand-based pharmacophore screening, dual-docking refinement, and molecular dynamics simulations, researchers evaluated small-molecule candidates against both oncogenic targets. In comparative simulations, ZINC2770543 demonstrated the most favorable overall binding profile among all evaluated compounds, maintaining stable hydrogen-bond interactions with key amino acid residues in both proteins and yielding favorable binding free energy values relative to standard reference drugs.

The study addresses a major signaling axis implicated in oncogenesis and cancer therapy failure. Src kinase and epidermal growth factor receptor (EGFR) operate as critical mediators within oncogenic signaling cascades that control cellular survival, proliferation, differentiation, and therapeutic resistance.

To discover dual-targeting candidates, the investigators implemented a multi-stage in silico screening strategy that began with ligand-based pharmacophore modeling. Distinct pharmacophore models were constructed for EGFR and Src to capture the critical chemical and spatial features necessary for binding each kinase. These models were then applied to screen purchasable chemical structures cataloged within the ZINC database, identifying hit molecules that matched the pharmacophore specifications of both target receptors.

The hit compounds selected from the pharmacophore screening underwent further structural refinement through molecular docking. The docking workflow utilized two separate computational docking tools, iGEMDOCK version 2.1 and AutoDock version 4.2, to evaluate ligand binding poses and interactions within the target binding sites. To provide a rigorous comparative benchmark, the docking simulations included two established reference inhibitors: erlotinib as the EGFR reference inhibitor and dasatinib as the Src reference inhibitor.

From the molecular docking analysis, six compounds were computationally prioritized as putative dual EGFR and Src binders. This selection was based on binding-pose persistence, specific residue interaction profiles, and comparative Molecular Mechanics/Poisson-Boltzmann Surface Area (MM/PBSA) binding free energy energetics. Among the prioritized group, ZINC2770543 emerged with the strongest dual-target binding profile. Subsequent molecular dynamics simulations confirmed that ZINC2770543 formed stable hydrogen bonds with essential residues in both EGFR and Src while maintaining advantageous binding free energy metrics compared to erlotinib and dasatinib.

Conducted by researchers at the School of Pharmacy at the Bandung Institute of Technology and published in Frontiers in Drug Discovery, the study provides a computational framework for dual-target lead discovery. The authors caution that the findings reflect in silico predictions and simulation energetics rather than direct biological measurements. Therefore, ZINC2770543 represents a computationally prioritized lead compound that warrants subsequent experimental validation in laboratory assays to verify its actual dual-inhibitory activity.

The investigation, authored by Junaidin Junaidin, Fransiska Kurniawan, and corresponding researcher Daryono Hadi Tjahjono, was formally evaluated within the journal’s section dedicated to in silico methods and artificial intelligence for drug discovery.

Subject of Research: Computational discovery of dual EGFR and Src kinase inhibitor candidates

Article Title: Integrated virtual screening in discovering dual EGFR and Src inhibitor candidates

Article References: Junaidin, J., Kurniawan, F., & Tjahjono, D. H. (2026). Integrated Virtual Screening in Discovering Dual EGFR and Src Inhibitor Candidates. Frontiers in Drug Discovery, 6, 1918390. https://doi.org/10.3389/fddsv.2026.1918390

Image Credits: AI Generated

DOI: 10.3389/fddsv.2026.1918390

Keywords: EGFR, Src kinase, dual-target inhibitors, virtual screening, pharmacophore modeling, molecular docking, molecular dynamics simulations, ZINC database, ZINC2770543, iGEMDOCK, AutoDock, erlotinib, dasatinib, MM/PBSA, binding free energy, oncogenic signaling, therapeutic resistance, in silico drug discovery

News Source: Ophelia Keating. (November 11, 2026). Computational Screening Identifies Candidate Compound ZINC2770543 as Putative Dual EGFR-Src Binder. Scienmag.

Tags: AutoDockbinding free energydasatinibdual-target inhibitorsEGFRerlotinibiGEMDOCKin silico drug discoveryMM/PBSAmolecular dockingmolecular dynamics simulationsoncogenic signalingpharmacophore modelingSrc kinasetherapeutic resistancevirtual screeningZINC databaseZINC2770543
Share12Tweet7Share2ShareShareShare1

Related Posts

Targeting Histone Lactylation With RNA Offers New Strategy Against Pancreatic Cancer

Targeting Histone Lactylation With RNA Offers New Strategy Against Pancreatic Cancer

November 16, 2026
Fluoride Varnish Reduces Tooth Decay by 43% in Permanent Teeth

Fluoride Varnish Reduces Tooth Decay by 43% in Permanent Teeth

November 16, 2026

Integrative Review Reframes Dental Caries as Dynamic Host Biofilm Tooth Interactions

November 16, 2026

African Research Initiatives Outline Lessons for Multi-Study Genomic Phenotype Harmonisation

November 16, 2026

POPULAR NEWS

  • Interferon-Induced LAP3 Promotes Mouse Embryo Resorption by Inhibiting Trophoblast Mitophagy

    Interferon-Induced LAP3 Promotes Mouse Embryo Resorption by Inhibiting Trophoblast Mitophagy

    29 shares
    Share 12 Tweet 7
  • Systematic Review Outlines Artificial Intelligence Strategies for Designing Functional Taste Peptides

    29 shares
    Share 12 Tweet 7
  • Biliary Fascioliasis Mimics Bile Duct Stones: Insights from Four Clinical Cases

    29 shares
    Share 12 Tweet 7
  • Physical Fitness Declined Among Belgian Children Between 2004 and 2022

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Targeting Histone Lactylation With RNA Offers New Strategy Against Pancreatic Cancer

Fluoride Varnish Reduces Tooth Decay by 43% in Permanent Teeth

Integrative Review Reframes Dental Caries as Dynamic Host Biofilm Tooth Interactions

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.